Journal article
High-Dose-Rate Rotte “Y” Applicator Brachytherapy for Definitive Treatment of Medically Inoperable Endometrial Cancer: 10-Year Results
International journal of radiation oncology, biology, physics, v 71(3), pp 779-783
01 Jul 2008
PMID: 18258388
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
To assess the intermediate clinical outcomes of medically inoperable patients with endometrial cancer treated with definitive Rotte “Y” applicator high-dose-rate brachytherapy (HDRB) over a 10-year period.
Forty-nine inoperable patients were treated with HDRB from 1997 to 2007. Forty three (84%) were markedly obese (body mass index >35 kg/m
2). Thirty-one patients (63.3%) underwent two-dimensional treatment planning, whereas 18 patients (36.7%) underwent three-dimensional treatment planning. Thirty five of the patients (71.4%) were first treated with external beam radiotherapy (EBRT). For patients receiving EBRT in addition to HDRB, the median Y-applicator dose was 20 Gy in 5 fractions; for patients receiving HDRB alone it was 35 Gy in 5 fractions. All patients received two Y-applicator treatments per day.
Median follow-up time for all patients was 33 months. Acute HDRB toxicities were limited to Grade 1 and 2 occurring in 5 patients. One patient had a myocardial infarction. Four patients had late Grade 2 or 3 toxicity. Three patients had local recurrence (median time to recurrence, 16 months). The 3- and 5-year actuarial cause-specific survival rates were 93% and 87%, respectively; the overall survival rate was 83% and 42%, respectively, at 3 and 5 years.
Twice-daily HDRB using a Y-applicator is a well-tolerated and efficacious regimen for the definitive treatment of medically inoperable patients with early-stage endometrial cancer. The recent incorporation of three-dimensional treatment planning has the potential to further decrease treatment morbidities.
Metrics
Details
- Title
- High-Dose-Rate Rotte “Y” Applicator Brachytherapy for Definitive Treatment of Medically Inoperable Endometrial Cancer: 10-Year Results
- Creators
- Devin Coon - UPMC Hillman Cancer CenterSushil Beriwal - University of PittsburghDwight E. Heron - University of PittsburghJoseph L. Kelley - UPMC Hillman Cancer CenterRobert P. Edwards - UPMC Hillman Cancer CenterPaniti Sukumvanich - UPMC Hillman Cancer CenterKristin K. Zorn - UPMC Hillman Cancer CenterThomas C. Krivak - UPMC Hillman Cancer Center
- Publication Details
- International journal of radiation oncology, biology, physics, v 71(3), pp 779-783
- Publisher
- Elsevier
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Radiation Oncology (and Nuclear Medicine)
- Web of Science ID
- WOS:000256572400020
- Scopus ID
- 2-s2.0-44449098185
- Other Identifier
- 991021897282204721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Oncology
- Radiology, Nuclear Medicine & Medical Imaging